Your browser is no longer supported. Please, upgrade your browser.
Settings
MACK Merrimack Pharmaceuticals, Inc. daily Stock Chart
MACK [NASD]
Merrimack Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.33 Insider Own0.70% Shs Outstand127.72M Perf Week-11.93%
Market Cap688.41M Forward P/E- EPS next Y-0.51 Insider Trans10.92% Shs Float117.00M Perf Month-19.91%
Income-151.70M PEG- EPS next Q-0.27 Inst Own67.80% Short Float18.35% Perf Quarter-37.76%
Sales95.70M P/S7.19 EPS this Y-66.60% Inst Trans5.11% Short Ratio12.31 Perf Half Y-33.37%
Book/sh-1.87 P/B- EPS next Y32.00% ROA-95.50% Target Price12.20 Perf Year-55.45%
Cash/sh1.04 P/C5.20 EPS next 5Y5.60% ROE88.50% 52W Range5.02 - 12.59 Perf YTD-31.77%
Dividend- P/FCF- EPS past 5Y-15.50% ROI- 52W High-56.83% Beta1.99
Dividend %- Quick Ratio1.60 Sales past 5Y34.50% Gross Margin99.20% 52W Low8.27% ATR0.33
Employees426 Current Ratio1.70 Sales Q/Q43.90% Oper. Margin- RSI (14)35.74 Volatility5.87% 5.07%
OptionableYes Debt/Eq- EPS Q/Q-2.20% Profit Margin- Rel Volume0.68 Prev Close5.39
ShortableYes LT Debt/Eq- EarningsAug 08 AMC Payout- Avg Volume1.74M Price5.43
Recom1.80 SMA20-12.65% SMA50-17.11% SMA200-28.73% Volume951,572 Change0.83%
May-27-16Initiated Robert W. Baird Neutral $8
Dec-23-15Reiterated Mizuho Buy $16 → $13
Oct-27-15Reiterated Oppenheimer Outperform $13 → $15
Apr-21-15Reiterated Mizuho Buy $13 → $16
Oct-10-14Resumed Oppenheimer Outperform $9 → $11
Jul-08-14Resumed Brean Capital Buy $16
Jun-20-14Reiterated Oppenheimer Outperform $10 → $8.50
Aug-09-13Reiterated Oppenheimer Outperform $12 → $10
Jun-25-13Initiated Mizuho Buy $12
May-08-12Initiated Oppenheimer Outperform $12
Jun-30-16 08:00AM  NAPOLI-1 Data Demonstrates ONIVYDE® Regimen Maintains Quality of Life While Improving Overall Survival in Patients with Metastatic Pancreatic Cancer PR Newswire
Jun-27-16 04:09PM  Here's Why Merrimack Pharmaceuticals' Stock Has Been Getting Crushed in 2016 at Motley Fool -7.36%
Jun-22-16 08:07AM  The Quest for an Effective Treatment for Pancreatic Cancer
Jun-21-16 04:32PM  Merrimack to Present New Analyses of Phase 3 NAPOLI-1 Data at the ESMO 18th World Congress on Gastrointestinal Cancer PR Newswire
Jun-16-16 04:56PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-09-16 09:30AM  The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics -5.20%
Jun-08-16 10:52AM  Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Jun-07-16 04:57PM  Merrimack Announces Positive Data on Oncology Candidate
Jun-06-16 07:30AM  Final Analysis of First-in-Human Phase 1 Study of MM-151 Shows Positive Clinical Activity in Multiple Solid Tumor Types, Including Colorectal Cancer PR Newswire
Jun-03-16 07:55AM  These 7 Stocks Under $10 Are About to Break Out
May-27-16 05:39AM  Coverage initiated on Merrimack Pharma by Robert W. Baird
May-20-16 02:37PM  Merrimack/Baxalta Start Study on Colorectal Cancer Drug
May-19-16 07:40PM  ETFs with exposure to Merrimack Pharmaceuticals, Inc. : May 19, 2016
02:20PM  Targeting cancer
07:05AM  Merrimack Announces a Leading-edge Biomarker-Selected, Multi-Arm Basket Trial that Matches Patients with Most Appropriate Combination Regimens PR Newswire
07:00AM  Merrimack and Baxalta Announce Initiation of Phase 1 Study of MM-151 in Combination with the ONIVYDE® (irinotecan liposome injection) Regimen in Metastatic Colorectal Cancer PR Newswire
May-18-16 05:10PM  Merrimack to Present on Extensive Oncology Pipeline at the 2016 American Society of Clinical Oncology Annual Meeting PR Newswire
May-17-16 04:05PM  Merrimack Presents Expanded Analysis from Seribantumab (MM-121) Phase 2 Breast Cancer Study at the AACR Precision Medicine Series PR Newswire
May-07-16 01:04PM  MERRIMACK PHARMACEUTICALS INC Financials
May-04-16 11:53AM  Merrimack Pharmaceuticals, Inc. :MACK-US: Earnings Analysis: Q1, 2016 By the Numbers
May-03-16 11:22AM  Why Merrimack Pharmaceuticals' Stock Is Sliding Today at Motley Fool -8.38%
11:22AM  Why Merrimack Pharmaceuticals' Stock Is Sliding Today at Motley Fool
10:33AM  Merrimack (MACK) Posts Narrower-than-Expected Loss in Q1
08:25AM  Sales of Merrimacks new pancreatic cancer drug top $11M in Q1 at bizjournals.com
May-02-16 10:56PM  Edited Transcript of MACK earnings conference call or presentation 2-May-16 8:30pm GMT
04:15PM  Merrimack reports 1Q loss AP
04:12PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements EDGAR Online
04:01PM  Merrimack Reports First Quarter 2016 Financial Results PR Newswire
07:07AM  Q1 2016 Merrimack Pharmaceuticals Inc Earnings Release - After Market Close CCBN
Apr-29-16 09:04AM  Drug Stocks Q1 Earnings Preview: AEGR, AERI, MACK, PRTA Zacks
Apr-28-16 01:30PM  ETFs with exposure to Merrimack Pharmaceuticals, Inc. : April 28, 2016 at Capital Cube
Apr-27-16 07:06PM  Merrimack (MACK) Q1 Earnings: What's Ahead for the Stock? Zacks
08:36AM  Merrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MACK-US : April 27, 2016 at Capital Cube
Apr-21-16 08:00AM  Merrimack Unveils its Latest Antibody Directed Nanotherapeutic, MM-310, at the 2016 AACR Annual Meeting PR Newswire
Apr-20-16 04:30PM  Merrimack Announces Timing of First Quarter 2016 Investor Conference Call PR Newswire
Apr-14-16 04:05PM  Leica Biosystems and Merrimack Pharmaceuticals to Collaborate on Development of a Heregulin Companion Diagnostic for Seribantumab PR Newswire -5.13%
01:21PM  What Is Going On With These Falling Stocks? at Insider Monkey
08:02AM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Eq
Apr-11-16 09:30AM  Zacks Investment Ideas feature highlights: Juno Therapeutics, Genocea Biosciences, Merrimack Pharmaceuticals and BioShares Biotechnology Clinical Trials ETF
08:40AM  3 Biotech Stocks With Scary-High Debt-to-Capital Ratios at Motley Fool
Apr-07-16 04:21PM  Merrimack Pharmaceuticals Inc Rose 28% in March. Here's Why. at Motley Fool
Mar-24-16 07:00AM  Merrimack Announces Inclusion of ONIVYDE® (irinotecan liposome injection) as a Category 1 Treatment Option in the 2016 NCCN Guidelines for Pancreatic Adenocarcinoma PR Newswire
Mar-16-16 04:45PM  Merrimack to Present on Multiple Oncology Programs at the 2016 American Association for Cancer Research Annual Meeting PR Newswire
Mar-14-16 12:39PM  XLV Rose Last Week, but Did It Reach Its 100-Day Moving Average?
Mar-03-16 09:38AM  Merrimack Pharmaceuticals, Inc. Value Analysis (NASDAQ:MACK) : March 3, 2016
Mar-02-16 11:49AM  Bears Had the Upper Hand on February 29: IBB Lost 2.8%
10:12AM  Merrimack Pharmaceuticals, Inc. Earnings Analysis: 2015 By the Numbers
08:27AM  Merrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MACK-US : March 2, 2016
08:15AM  Merrimack Pharmaceuticals (MACK) Jumps: Stock Rises 12.6%
Feb-26-16 03:31PM  Merrimack Q4 Loss in Line with Estimates, Revenues Miss
01:52PM  Edited Transcript of MACK earnings conference call or presentation 25-Feb-16 9:30pm GMT
01:14PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
Feb-25-16 05:55PM  Merrimack reports 4Q loss
04:21PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:01PM  Merrimack Reports Fourth Quarter 2015 Financial Results PR Newswire
07:07AM  Q4 2015 Merrimack Pharmaceuticals Inc Earnings Release - After Market Close
Feb-22-16 03:02PM  [$$] Buy-Rated Biotechs to Report Earnings at Barrons.com
11:50AM  What's in Store for Merrimack (MACK) this Earnings Season?
Feb-17-16 08:00AM  Merrimack Announces Timing of Fourth Quarter 2015 Investor Conference Call PR Newswire
Feb-12-16 04:51PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Feb-11-16 08:30AM  How to Beat the Market with Biotech -- Bluebird bio, Halozyme Therapeutics, Merrimack Pharma, and Kite Pharma Accesswire
Feb-04-16 02:14PM  Merrimack CEO: Face of pharma isn't a bad actor
Jan-20-16 04:36PM  Merrimack Reports Positive Onivyde Data in Pancreatic Cancer +10.39%
Jan-19-16 06:58PM  Updated Data Shows ONIVYDE® (irinotecan liposome injection) Combination Regimen Increased One Year Survival by 63% in Patients with Metastatic Pancreatic Cancer PR Newswire
Jan-13-16 06:24AM  3 Biotech Stocks Under $10 to Trade for Big Breakouts at TheStreet -8.14%
Jan-11-16 08:00AM  Merrimack to Present Updated Overall Survival Analysis of Phase 3 NAPOLI-1 Study of ONIVYDE (irinotecan liposome injection) at the American Society of Clinical Oncology (ASCO) 2016 Gastrointestinal Cancers Symposium PR Newswire -11.55%
Jan-05-16 08:00AM  Merrimack to Present at the 34th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-29-15 08:30AM  A Refreshing Outlook - Research Reports on Cobalt International Energy, Merrimack Pharmaceuticals, Spectranetics and Jinpan International Accesswire
Dec-23-15 04:51PM  Merrimack Alters Endpoint in Cancer Drug Trial, Raises Funds
Dec-22-15 04:39PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Materi
04:16PM  Merrimack Amends MM-121 Phase 2 Clinical Study in Heregulin-Positive Non-Small Cell Lung Cancer to Support Potential Registration PR Newswire
04:15PM  Merrimack Announces Private Placement of $175 Million of Senior Secured Notes PR Newswire
Dec-15-15 11:20AM  Massachusetts biotechs behind one-in-six drugs approved by FDA this year at bizjournals.com
Dec-14-15 02:14PM  Merrimack Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers -5.61%
Dec-13-15 12:34PM  Do Hedge Funds Love Merrimack Pharmaceuticals Inc (MACK)? at Insider Monkey
Dec-12-15 08:40PM  Do Hedge Funds Love Ollies Bargain Outlet Holdings Inc (OLLI)? at Insider Monkey
Dec-04-15 08:00AM  Merrimack Announces Presentations at the 2015 San Antonio Breast Cancer Symposium PR Newswire +5.31%
Nov-30-15 10:59AM  Merrimack Pharmaceuticals, Inc. Value Analysis (NASDAQ:MACK) : November 30, 2015
08:09AM  Merrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : November 30, 2015
Nov-25-15 02:24PM  Baxaltas ONIVYDE NAPOLI-1 Study Sends It to Top of Large-Caps
08:14AM  Hedge Funds Are Buying A. Schulman Inc (SHLM) at Insider Monkey
Nov-24-15 05:02PM  Merrimack CFO Brings Banking, Clinical Chops to Role at The Wall Street Journal
Nov-23-15 08:00AM  Merrimack and Baxalta Announce Publication of the ONIVYDE (irinotecan liposome injection) NAPOLI-1 Study in The Lancet PR Newswire +6.06%
Nov-21-15 01:15PM  JPMorgan Likes These 5 Biotech Stocks at TheStreet
Nov-19-15 02:30PM  Gilead Leads a Biotech Rally at TheStreet
Nov-16-15 03:35PM  Momenta's Cancer Study Enrolment Put on Temporary Hold -5.92%
Nov-10-15 03:03PM  Why Merrimack Pharmaceuticals Inc Is Selling Off Today at Motley Fool -9.06%
02:15PM  Merrimack (MACK) Reports Narrower-than-Expected Q3 Loss
Nov-09-15 10:03PM  Edited Transcript of MACK earnings conference call or presentation 9-Nov-15 9:30pm GMT
05:25PM  Merrimack reports 3Q loss
04:21PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:02PM  Merrimack Reports Third Quarter 2015 Financial Results PR Newswire
07:07AM  Q3 2015 Merrimack Pharmaceuticals Inc Earnings Release - After Market Close
Nov-06-15 03:25PM  Will Puma Biotechnology (PBYI) Surprise in Q3 Earnings?
02:55PM  Will Merrimack (MACK) Surprise Estimates in Q3 Earnings?
02:40PM  Will Intercept (ICPT) Beat Estimates in Q3 Earnings?
01:40PM  Will Inovio (INO) Disappoint Investors this Earnings Season?
Nov-05-15 04:25PM  What Awaits Ligand Pharmaceuticals (LGND) in Q3 Earnings?
04:20PM  Will Isis Pharmaceuticals (ISIS) Surprise in Q3 Earnings?
06:42AM  CEO: THIS is biggest threat to pharm research...
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. Its therapeutic oncology candidates in clinical development include MM-398, which is in Phase II clinical trials for the treatment of patients with previously untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trials for the treatment of patients with glioma, pediatric solid tumors, and gastrointestinal tumors; and Phase I clinical trials for treating metastatic breast cancer. The company's therapeutic oncology candidates also include MM-302 that is in Phase II clinical trials for the treatment of patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer. In addition, its therapeutic oncology candidates consist of MM-141 that is in Phase II clinical trials for the treatment of previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1; and MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has license and collaboration agreements with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; development, license, and supply agreement with Watson Laboratories, Inc.; sublicense and collaboration agreement with PharmaEngine, Inc.; collaboration agreements with Dyax Corp. and Adimab LLC,; and license agreement with University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PORTER MICHAEL EDirectorMar 17Buy7.205,00036,000754,448Mar 21 09:25 AM
PORTER MICHAEL EDirectorMar 15Buy7.655,00038,250749,448Mar 17 10:51 AM
PORTER MICHAEL EDirectorMar 08Buy7.0910,00070,900744,448Mar 10 09:28 AM
PORTER MICHAEL EDirectorMar 03Buy6.2710,00062,700734,448Mar 04 09:02 AM
PORTER MICHAEL EDirectorMar 02Buy6.635,00033,150724,448Mar 04 09:02 AM
PORTER MICHAEL EDirectorMar 01Buy6.6010,00066,000719,448Mar 02 11:13 AM
McClements William M.Head of Corporate OperationsFeb 29Buy5.722,00011,44014,072Mar 01 01:54 PM
PORTER MICHAEL EDirectorFeb 29Buy5.6110,00056,100709,448Mar 02 11:13 AM
Lee Vivian SDirectorFeb 29Buy5.5035,000192,50065,000Feb 29 02:57 PM
Stewart Edward J.Head of CommercialJan 05Option Exercise1.814,0007,24025,385Jan 07 06:41 PM
Stewart Edward J.Head of CommercialJan 05Sale8.004,00032,00021,385Jan 07 06:41 PM
Stewart Edward J.Head of CommercialDec 01Option Exercise1.815,0009,05026,385Dec 03 04:53 PM
Stewart Edward J.Head of CommercialDec 01Sale9.335,00046,65021,385Dec 03 04:53 PM
Stewart Edward J.Head of CommercialOct 16Option Exercise1.811,0001,81022,385Oct 16 07:09 PM
Stewart Edward J.Head of CommercialOct 16Sale10.001,00010,00021,385Oct 16 07:09 PM
Stewart Edward J.Head of CommercialOct 02Option Exercise1.811,0001,81022,385Oct 05 04:11 PM
Stewart Edward J.Head of CommercialOct 02Sale9.001,0009,00021,385Oct 05 04:11 PM
Stewart Edward J.Head of CommercialOct 01Option Exercise1.814,0007,24025,385Oct 05 04:11 PM
Stewart Edward J.Head of CommercialOct 01Sale8.004,00032,00021,385Oct 05 04:11 PM
Stewart Edward J.Head of CommercialSep 01Option Exercise1.816,00010,86027,385Sep 01 04:11 PM
Stewart Edward J.Head of CommercialSep 01Sale9.886,00059,28021,385Sep 01 04:11 PM
PORTER MICHAEL EDirectorAug 21Buy9.765,00048,800699,448Aug 25 09:13 AM
Stewart Edward J.Head of CommercialAug 17Option Exercise1.816,00010,86027,385Aug 19 04:09 PM
Stewart Edward J.Head of CommercialAug 17Sale10.496,00062,94021,385Aug 19 04:09 PM
PORTER MICHAEL EDirectorAug 14Buy10.183,00030,540694,448Aug 17 09:00 AM
PORTER MICHAEL EDirectorAug 13Buy10.6510,000106,500691,448Aug 17 09:00 AM
Lee Vivian SDirectorAug 12Buy10.0510,000100,50030,000Aug 14 09:21 AM
Dineen John M.DirectorAug 12Buy10.15100,0001,015,000100,000Aug 13 08:34 AM
PORTER MICHAEL EDirectorAug 12Buy10.1620,000203,200681,448Aug 13 08:30 AM
Stewart Edward J.Head of CommercialJul 15Option Exercise1.816,00010,86027,385Jul 17 04:10 PM
Sullivan William A.CFO and TreasurerJul 15Option Exercise2.1215,00031,80026,000Jul 17 04:11 PM
Sullivan William A.CFO and TreasurerJul 15Sale11.8515,000177,75011,000Jul 17 04:11 PM
Stewart Edward J.Head of CommercialJul 15Sale11.846,00071,04021,385Jul 17 04:10 PM